scFv-mediated delivery of truncated BID suppresses HER2-positive osteosarcoma growth and metastasis

Cancer Biology and Therapy

Volumn 7, Issue 11, 2008, Pages 1717-1722

  Shan, Le Qun ^a   Qiu, Xiu Chun ^a   Xu, Yan Ming ^b   Ji, Zheng Gang ^a   Yang, Tong Tao ^a   Chen, Xiang ^a   Ma, Bao An ^a   Zhou, Yong ^a   Fan, Qing Yu ^a   Yang, An Gang ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; BID; Gene therapy; HER2 neu; Osteosarcoma

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIPOSOME; PACLITAXEL; PROTEIN BID; PROTEIN E23SFV PEA II BID DELTA1 60; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; APOPTOSIS INDUCING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN FRAGMENT;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFICACY; EXPRESSION VECTOR; GENE OVEREXPRESSION; GENE REPRESSION; GENE VECTOR; GENETIC CODE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METASTASIS; METASTASIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CHEMISTRY; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; HELA CELL; METABOLISM; METHODOLOGY;

ANIMALS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HELA CELLS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; OSTEOSARCOMA; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 56449118531     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.11.6727     Document Type: Article

References (36)

1. Luo X, Budlhardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94:481-90.
2. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev 1996; 10:2859-69.
3. Cosulich SC, Worrall V, Hedge PJ, Green S, Clarke PR. Regulation of apoptosis by BH3 domains in a cell-free system. Curr Biol 1997; 7:913-20.
4. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94:491-501.
5. Yin XM. Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways. Cell Res 2000; 10:161-7.
6. Hayden JB, Hoang BH. Osteosarcoma: basic science and clinical implications. Orthop Clin North Am 2006; 37:1-7.
7. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006; 32:423-36.
8. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006; 6:1075-85.
9. Fang B, Roth JA. Tumor-suppressing gene therapy. Cancer Biol Ther 2003; 2:115-21.
10. Pearson S, Jia H, Kandachi K. China approves first gene therapy. Nat Biotechnol 2004; 22:3-4.
11. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986; 319:226-30.
12. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988; 48:1238-43.
13. Akatsuka T, Wada T, Kokai Y, Kawaguchi S, Isu K, Yamashiro K, Yamashita T, Sawada N, Yamawaki S, Ishii S. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002; 94:1397-404.
14. Somers GR, Ho M, Zielenska M, Squire JA, Thorner PS. HER2 amplification and over-expression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol 2005; 8:525-32.
15. Lee WI, Bacchni P, Bertoni F, Maeng YH, Park YK. Quantitative assessment of HER2/neu expression by real-time PCR and fluorescent in situ hybridization analysis in low-grade osteosarcoma. Oncol Rep 2004; 12:125-8.
16. Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 2002; 8:788-93.
17. Scotlandi K, Manara MC, Hattinger CM, Benini S, Perdichizzi S, Pasello M, Bacci G, Zanella L, Bertoni F, Picci P, Serra M. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005; 41:1349-61.
18. Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, Meyers PA. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999; 17:2781-8.
19. Chen X, Yang TT, Ma BA, Fan QY. Establishment of human osteosarcoma cell sublines with different potential of metastasis and studies on their biological characteristics. J Fourth Mil Med Univ 2005; 26:1992-5.
20. Pelegrin M, Marin M, Noel D, Piechaczyk M. Genetically engineered antibodies in gene transfer and gene therapy. Hum. Gene Ther 1998; 9:2165-75.
21. Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochem Biophys Res Commun 2001; 280:274-9.
22. Schneider PM, Praeuer HW, Stoeltzing O, Boehm J, Manning J, Metzger R, Fink U, Wegerer S, Hoelscher AH, Roth JA. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer 2000; 83:473-9.
23. Rasmuson T, Grankvist K, Ljungberg B. Soluble ectodomain of c-erbB-2 oncoprotein in relation to tumour stage and grade in human renal cell carcinoma. Br J Cancer 1997; 75:1674-7.
24. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-12.
25. Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A. HER2 as a prognostic factor in breast cancer. Oncology 2001; 61:67-72.
26. Wels W, Harwerth IM, Mueller M, Groner B, Hynes NE. Selective inhibition of tumor cell growth by a recombinant single-chain antibody specific for the erbB-2 receptor. Cancer Res 1992; 52:6310-7.
27. Roh H, Pippin JA, Green DW, Boswell CB, Hirose CT, Mokadam N, Drebin JA. HER2/ neu antisense targeting of human breast carcinoma. Oncogene 2000; 19:6138-43.
28. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 1996; 14:737-44.
29. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19:2587-95.
30. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:1800-8.
31. Posey JA, Khazaeli MB, Bookman MA, Nowrouzi A, Grizzle WE, Thornton J, Carey DE, Lorenz JM, Sing AP, Siegall CB, LoBuglio AF, Saleh MN. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002; 8:3092-9.
32. Yu CJ, Jia LT, Meng YL, Zhao J, Zhang Y, Qiu XC, Xu YM, Wen WH, Yao LB, Fan DM, Jin BQ, Chen SY, Yang AG. Selective proapoptotic activity of a secreted recombinant antibody/AIF fusion protein in carcinomas overexpressing HER2. Gene Ther 2006; 13:313-20.
33. Xu YM, Wang LF, Jia LT, Qiu XC, Zhao J, Yu CJ, Zhang R, Zhu F, Wang CJ, Jin BQ, Chen SY, Yang AG. A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors. J Immunol 2004; 173:61-7.
34. Zhao J, Zhang LH, Jia LT, Zhang L, Xu YM, Wang Z, Yu CJ, Peng WD, Wen WH, Wang CJ, Chen SY, Yang AG. Secreted antibody/granzyme B fusio n protein stimulates selective killing of HER2-overexpressing tumor cells. J Biol Chem 2004; 279:21343-8.
35. Jia LT, Zhang LH, Yu CJ, Zhao J, Xu YM, Gui JH, Jin M, Ji ZL, Wen WH, Wang CJ, Chen SY, Yang AG. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res2003; 63:3257-62.
36. Shafique QS, Rajesh CM, Rakesh SN. Cardiac metastases of osteosarcoma. J Coll Physicians Surg Pak 2004; 14:430-2.